Inventor
FRYE KELLY
US24 patents
⚠️ This page may combine multiple inventors who share the name “FRYE KELLY”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
18 patentsUS10464992B2Nov 5, 2019
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA60 citations99
US10400025B2Sep 3, 2019
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA54 citations99
US9914763B2Mar 13, 2018
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA56 citations99
US9580489B2Feb 28, 2017
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA67 citations99
US9340594B2May 17, 2016
VEGF antagonist formulations for intravitreal administration
REGENERON PHARMA73 citations99
US8802107B2Aug 12, 2014
VEGF antagonist formulations for intravitreal administration
REGENERON PHARMA65 citations99
US10406226B2Sep 10, 2019
Method of manufacturing VEGF antagonist fusion proteins
REGENERON PHARMA70 citations98
US9511140B2Dec 6, 2016
Stable VEGF antagonist formulations
REGENERON PHARMA62 citations98
US9416167B2Aug 16, 2016
Stable liquid formulations of dimer VEGF antagonists
REGENERON PHARMA62 citations98
US8921316B2Dec 30, 2014
Stable liquid VEGF antagonist formulations
REGENERON PHARMA62 citations98
US7807164B2Oct 5, 2010
Lyophilized VEGF antagonist formulations for intravitreal administration
REGENERON PHARMA83 citations98
US9636400B2May 2, 2017
VEGF specific fusion protein antagonist formulations
REGENERON PHARMA59 citations97
US11084865B2Aug 10, 2021
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA14 citations94
US11066458B2Jul 20, 2021
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA12 citations94
US10857231B2Dec 8, 2020
Formulations of VEG antagonist fusion proteins and method of manufacturing them
REGENERON PHARMA9 citations92
US11732024B2Aug 22, 2023
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA2 citations84
US12331099B2Jun 17, 2025
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA0 citations73
US11806398B2Nov 7, 2023
Citrate buffered VEGF antagonist formulations
REGENERON PHARMA1 citations73